Mycotoxin Testing for Traditional Chinese Medicinal Herbs: Analytical Methods and Regulatory Complia

Mycotoxin testing is a critical safety control for traditional Chinese medicinal herbs, which are highly susceptible to contamination by toxigenic fungi during cultivation, harvesting, drying, and prolonged storage. Accredated laboratories apply validated HPLC-FLD and LC-MS/MS methods to quantify aflatoxins, ochratoxin A, and other regulated mycotoxins at microgram-per-kilogram levels in accordance with pharmacopoeial and international requirements. This technical article reviews the sample types, target analytes, analytical procedures, quality assurance practices, and applications of mycotoxin analysis in the herbal medicine industry.

Technical Overview

Mycotoxins are low-molecular-weight secondary metabolites produced by filamentous fungi, principally Aspergillus, Penicillium, and Fusarium species. In traditional Chinese medicine (TCM) materia medica, the most significant contaminants include aflatoxins B1, B2, G1, and G2 produced by Aspergillus flavus and A. parasiticus, ochratoxin A produced by A. ochraceus and Penicillium verrucosum, and trichothecenes, zearalenone, and fumonisins produced by various Fusarium species. Aflatoxin B1 is classified by the International Agency for Research on Cancer (IARC) as a Group 1 human carcinogen, while ochratoxin A is nephrotoxic and potentially carcinogenic.

Herbal materials are intrinsically vulnerable to fungal contamination because they consist of roots, rhizomes, seeds, kernels, and flowers rich in starch, protein, and lipids. Field cultivation, open-air sun drying, humid storage environments, and long supply-chain cycles all create conditions favorable for toxigenic fungal growth and mycotoxin biosynthesis. Because mycotoxins are chemically stable and survive typical processing steps such as washing, steaming, and drying, testing of the finished material is the only reliable means of verification.

The current edition of the Chinese Pharmacopoeia mandates aflatoxin testing for a defined list of herbal monographs, with a limit of not more than 5 micrograms per kilogram for aflatoxin B1 and not more than 10 micrograms per kilogram for the sum of aflatoxins B1, B2, G1, and G2, together with ochratoxin A limits for selected drugs. Comparable requirements exist in USP General Chapter <561> Articles of Botanical Origin, EU Commission Regulation (EU) 2023/915, and the import specifications of Japan, Southeast Asian markets, and the World Health Organization botanical quality guidelines. Systematic mycotoxin testing is therefore indispensable for pharmacopoeial release, GMP compliance, and international trade.

Testing Samples

Roots and Rhizomes

High-starch materials such as licorice root, astragalus root, angelica root, notoginseng, and salvia are among the most commonly tested categories. Their dense, starchy matrices retain moisture readily, supporting Aspergillus proliferation during drying and bulk storage.

Seeds, Kernels, and Fruits

Oily and proteinaceous materials including coix seed, apricot kernel, peach kernel, areca seed, and tangerine peel exhibit a well-documented propensity for aflatoxin accumulation and are prioritized in pharmacopoeial surveillance programs.

Flowers, Leaves, and Whole Herbs

Flos carthami, chrysanthemum, honeysuckle, and whole-herb materials are tested to evaluate contamination introduced during blossom drying and bale storage, particularly for ochratoxin A and aflatoxins.

Powders, Extracts, and Finished Preparations

Ground herbal powders, granules, concentrated extracts, and compound formulations are analyzed with matrix-adapted extraction procedures, since extraction solvents and cleanup strategies must account for polysaccharide, tannin, and glycoside interferences.

Stored and Stability Samples

Retained samples from commercial storage lots and long-term stability studies are tested periodically to monitor mycotoxin formation over shelf life and to validate warehouse humidity and temperature controls.

Testing Items

Testing panels are configured according to pharmacopoeial monographs, destination-market regulations, and the risk profile of the botanical matrix. Core and extended analytes include the following:

• Aflatoxin B1: IARC Group 1 carcinogen; the single most regulated mycotoxin, with a Chinese Pharmacopoeia limit of 5 micrograms per kilogram in tested herbal drugs.
• Total aflatoxins (B1 + B2 + G1 + G2): typically limited to 10 micrograms per kilogram, with stricter limits of 2 micrograms per kilogram for aflatoxin B1 in certain export markets.
• Ochratoxin A: nephrotoxic analyte regulated for selected botanicals in the Chinese Pharmacopoeia, EU, and Swiss and German pharmacopoeial guidance for herbal drugs.
• Zearalenone: estrogenic Fusarium toxin relevant to seed-derived and cereal-adulterated materials.
• Deoxynivalenol (vomitoxin) and nivalenol: type B trichothecenes monitored in coix seed and grain-related herbs.
• T-2 and HT-2 toxins: type A trichothecenes with immunosuppressive activity.
• Fumonisins B1 and B2: monitored in matrices associated with Fusarium verticillioides contamination.
• Sterigmatocystin: biosynthetic precursor of aflatoxin B1 and an emerging surveillance target.
• Multi-mycotoxin screening panels: liquid chromatography-tandem mass spectrometry (LC-MS/MS) screens covering dozens of regulated and emerging mycotoxins, masked mycotoxins, and fungal metabolites in a single run.

Testing Methods

Sample Preparation

Representative laboratory samples are milled to a homogeneous fine powder. Mycotoxins are extracted with aqueous methanol (typically 70 percent) or acetonitrile-water mixtures under ultrasonic or mechanical agitation. For aflatoxins and ochratoxin A, extracts are cleaned up on immunoaffinity columns to remove matrix pigments, tannins, and lipids prior to chromatographic analysis. For broad multi-analyte panels, dilute-and-shoot, dispersive solid-phase extraction, or QuEChERS-based protocols are applied, with carbon-13 isotope-labeled internal standards compensating for matrix effects.

HPLC with Fluorescence Detection (HPLC-FLD)

HPLC-FLD remains the pharmacopoeial reference technique for aflatoxins and ochratoxin A. Aflatoxins are separated on a reversed-phase C18 column and enhanced through post-column derivatization by photochemical reaction or electrochemical bromination, achieving detection limits at or below 0.2 micrograms per kilogram. Ochratoxin A is quantified using its native fluorescence, typically with excitation at 333 nanometers and emission at 460 nanometers.

LC-MS/MS Confirmation

Tandem mass spectrometry enables simultaneous quantification of multiple mycotoxin classes in a single injection using multiple-reaction-monitoring transitions, for example m/z 313 to 241 and 285 for aflatoxin B1 and m/z 404 to 239 and 358 for ochratoxin A. Matrix-matched calibration combined with isotopically labeled standards delivers limits of quantification in the range of 0.05 to 1 microgram per kilogram and confirms screening positives with full legal defensibility.

Rapid Screening

Enzyme-linked immunosorbent assay (ELISA) kits and lateral-flow immunochromatographic strips provide cost-effective, high-throughput screening for aflatoxins and ochratoxin A at warehouse receiving and production intake. All presumptive positive results are confirmed by chromatographic methods before regulatory or contractual decisions are made.

Method Validation and Quality Assurance

Methods are validated for specificity, linearity, accuracy, precision, and limits of detection and quantification in accordance with the performance criteria of EU method-validation guidance for mycotoxin analysis. Routine quality control includes certified reference materials, spike-recovery experiments, matrix blanks, and participation in interlaboratory proficiency testing, all within an ISO/IEC 17025-accredited management system.

Applications

Mycotoxin testing supports the herbal medicine sector across the entire product lifecycle:

• Pharmacopoeial release testing of herbal drugs and Chinese medicinal slices against Chinese Pharmacopoeia, USP, and EP limits.
• GMP raw-material acceptance control and supplier qualification for TCM manufacturers and extract producers.
• Import and export inspection for shipments destined to the European Union, North America, Japan, and Southeast Asian markets.
• Good Agricultural Practice (GAP) origin management, including evaluation of drying, packaging, and warehouse conditions at cultivation bases.
• Shelf-life and stability studies verifying that mycotoxin levels remain within specification throughout distribution.
• Scientific research on fungal ecology, contamination pathways, and control strategies in medicinal plant production.

FAQ

Why are Chinese medicinal herbs particularly prone to mycotoxin contamination?

Herbal materials combine nutrient-rich matrices with traditional post-harvest handling such as open-air drying, bulk stacking, and long storage periods. Elevated moisture content above approximately 12 percent, together with warm and humid ambient conditions, promotes growth of Aspergillus and Fusarium species and subsequent mycotoxin production.

Which mycotoxins are legally required to be tested?

For pharmacopoeial compliance, aflatoxins B1, B2, G1, and G2 are mandatory for the listed monographs in the Chinese Pharmacopoeia, and ochratoxin A is required for selected herbal drugs. Destination-market regulations, such as EU Regulation 2023/915, may impose additional or stricter limits for export consignments.

How much sample is required, and how should sampling be performed?

Laboratories typically request 100 to 500 grams of milled homogeneous material. Because mycotoxins distribute heterogeneously in so-called hot spots, regulatory sampling should follow incremental-sampling schemes in which numerous subsamples drawn from different points of the lot are combined into a single aggregate sample before milling.

What is the difference between screening and confirmatory testing?

ELISA and lateral-flow assays are rapid, low-cost screening tools suitable for high-volume intake control but are subject to matrix cross-reactivity. HPLC-FLD and LC-MS/MS are confirmatory techniques that provide legally defensible identification and quantification and are required for batch release and dispute resolution.

Can extracts, granules, and finished TCM preparations be tested?

Yes. Matrix-adapted extraction and cleanup protocols allow accurate analysis of concentrated extracts, granules, honey-fried and steam-processed slices, and compound formulations, with isotope-dilution LC-MS/MS compensating for the stronger matrix effects encountered in these products.

What is the typical turnaround time?

Standard chromatographic testing is generally completed within five to ten working days from sample receipt, while rapid immunological screening can return results within one to two days for time-sensitive intake decisions.